This page shows what was measured, who it was measured in, and what that does not settle.
What Brodalumab does in the body
Moderate to severe plaque psoriasis
From the FDA-approved label: Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL-17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · 6ZA31Y954Z · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 86 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12
✗ The study did not show it
Who was studied
NCT01708629
How many people
1881
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12
✗ The study did not show it
Who was studied
NCT01708603
How many people
1831
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 at Week 12
✗ The study did not show it
Who was studied
NCT01708590
How many people
661
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16
✗ The study did not show it
Who was studied
NCT02024646
How many people
484
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
American College of Rheumatology (ACR) 20 Response
✗ The study did not show it
Who was studied
NCT02029495
How many people
478
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24
✗ The study did not show it
Who was studied
NCT01902290
How many people
421
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.1 registered measure of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
□Cells in a dishNo evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
clinical global impression
Measured
Things only a test, a scale or a device shows.
maximum observed concentration
Meaningful
Things that change how a life goes, not only a number.
who achieved clinical remission
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (15)
treatment emergent adverse events
an american college of rheumatology 50 response at week 12
treatment emergent adverse event
psoriasis area and severity index
safety
static physician global assessment success at week 12
psoriasis area severity index 75 at week 12
psoriasis area severity index 100 at week 12
american college of rheumatology 20 response
pasi improvement
hidradenitis suppurativa clinical response
biomarkers at week 12
biomarkers at week 24
incidence of treatment emergent adverse events
adverse events
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
SILIQ ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of SILIQ have not been evaluated in pediatric patients.”
US prescribing information · 1a550c33-456a-4833-814e-8591aea7c688 · read 2026-08-30
On older people, the label states: “Of the 3,066 plaque psoriasis subjects initially randomized to SILIQ in clinical trials, 192 (6%) were ≥ 65 years old and no subjects were ≥ 75 years old.”
US prescribing information · 1a550c33-456a-4833-814e-8591aea7c688 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary There are no human data on SILIQ use in pregnant women to inform a drug-associated risk.”
US prescribing information · 1a550c33-456a-4833-814e-8591aea7c688 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of brodalumab in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · 1a550c33-456a-4833-814e-8591aea7c688 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S5, S6.
No source is stored against this line.
What is in the pack
Sold as injectable, injection, given by the injection, subcutaneous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Brodalumab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 147 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
psoriasis — 36 reaction mentions
arthralgia — 33 reaction mentions
depression — 15 reaction mentions
suicidal ideation — 13 reaction mentions
psoriatic arthropathy — 12 reaction mentions
therapy interrupted — 10 reaction mentions
oropharyngeal pain — 9 reaction mentions
arthritis — 7 reaction mentions
cellulitis — 7 reaction mentions
cutaneous lymphoma — 5 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
3 products list this as an active ingredient in the United States drug directory. 3 of them contain it and nothing else.
FDA National Drug Code directory · 68225-086 · read 2026-08-29
They are sold as injection and solution, taken subcutaneous.
FDA National Drug Code directory · 68225-086 · read 2026-08-29
The regulator's established pharmacologic class for it is antibodies, interleukin 17 receptor a antagonists [moa] and interleukin-17 receptor a antagonist [epc].
FDA National Drug Code directory · 68225-086 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 1a550c33-456a-4833-814e-8591aea7c688 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 1a550c33-456a-4833-814e-8591aea7c688 · read 2026-08-29
Siliq is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: 210 mg/1.5 mL solution in a single-dose prefilled syringe., recorded as fda label in effect 2026-05-28 in the United States.
US prescribing information · 1a550c33-456a-4833-814e-8591aea7c688 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Brodalumab studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Brodalumab are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
6ZA31Y954Z
RxNorm concept
1872256
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S5, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was BLA761032, approved 20170215 to VALEANT LUXEMBOURG.
This order is fixed in code and does not count clicks or time on the page.
What is not here
7 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (10)
Q2
What did Brodalumab's largest trial (3500 people) and its longest (14 years) measure?
3500 people in Brodalumab's largest registered study, 14 years in its longest registered window, measuring The Maximum Observed Concentration of Midazolam After a Single Dose of Brodalumab. ClinicalTrials.gov · 2026-09-01
13 phase3, 12 phase2, 8 phase4, 6 phase1, 3 early phase1, 3 na or unstated; NCT03254667; 2031-11; no ageing endpoint recorded. Last human test completed 2026, NCT04306315.
Interpretation These counts include studies where Brodalumab was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase3
13
phase2
12
phase4
8
phase1
6
early phase1
3
na or unstated
3
1 more recorded row
Last recorded human testNCT04306315
2026-01-05
recorded 2026-09-01 · last checked 2026-09-04
Q3
Brodalumab was tested only in human — what did it show?
"Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)"; 14 of 44 registered studies
Show the evidence
Trial
NCT01059448
terminated; "Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)"
NCT01101100
terminated; "Sponsor Decision"
NCT01150890
terminated; "The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups"
NCT01199302
terminated; "The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups."
NCT01708590
terminated; "Sponsor decision"
NCT01708603
terminated; "Sponsor decision"
8 further recorded trials
NCT01708629
terminated; "Sponsor decision"
NCT01902290
terminated; "Study terminated early due to lack of efficacy observed following interim analysis in Q2 2015. Study Closed once all sites were closed in eClinical"
NCT02029495
terminated; "Sponsor Decision"
NCT02429882
withdrawn; "Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab, study is being cancelled/closed."
NCT02786732
terminated; "Sponsor"
NCT04249713
withdrawn; "Biomarker Samples Not Collected"
NCT04305327
terminated; "Early terminated due to difficulty recruiting participants"
NCT04533737
terminated; "The recruitment was terminated early due to delays and slow recruitment that significantly jeopardized the trial timelines. There were no safety concerns related to the early termination of the trial."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Brodalumab used 210 mg brodalumab — over how long?
5 recorded entries; human; also "210 mg brodalumab", "140 mg brodalumab", "Brodalumab 210 mg"
Show the evidence
human
NCT01708590
210 mg brodalumab
NCT01708590
140 mg brodalumab
NCT02429882
Brodalumab 210 mg
NCT02786732
210mg Brodalumab
NCT02786732
140mg Brodalumab
recorded 2026-09-01 · last checked 2026-09-04
Q6
Which of adverse events, american college of rheumatology 20 response and an american college of rheumatology 50 response at week 12 did Brodalumab's trials measure?
adverse events, american college of rheumatology 20 response and an american college of rheumatology 50 response at week 12 lead 18 outcome terms across Brodalumab's trials. ClinicalTrials.gov · 2026-09-01
psoriasis area and severity index, who achieved clinical remission, safety, static physician global assessment success at week 12, psoriasis area severity index 75 at week 12 and psoriasis area severity index 100 at week 12 follow.
Show the evidence
treatment emergent adverse events
1
an american college of rheumatology 50 response at week 12
1
treatment emergent adverse event
1
psoriasis area and severity index
1
who achieved clinical remission
1
safety
1
12 more recorded rows
static physician global assessment success at week 12
1
psoriasis area severity index 75 at week 12
1
psoriasis area severity index 100 at week 12
1
clinical global impression
1
american college of rheumatology 20 response
1
pasi improvement
1
maximum observed concentration
1
hidradenitis suppurativa clinical response
1
biomarkers at week 12
1
biomarkers at week 24
1
incidence of treatment emergent adverse events
1
adverse events
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Brodalumab's 4 ongoing trials reports first?
maximum observed concentration (Cmax); Assess the incidence of malignancy; latest 2031-11
Show the evidence
Trial
NCT03240809
"An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects"; n 2; "maximum observed concentration (Cmax)"; 2029-06
NCT03254667
"LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis"; n 3500; "Assess the incidence of malignancy"; 2031-11
NCT05132231
"Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity"; n 394; "The percentage change from baseline of the Dermatology Life Quality Index (DLQI) at 3 months, 6 months, and 12 months post-brodalumab initiation."; 2026-03-31
NCT06673329
"Brodalumab in the Treatment of Immune-Related Adverse Events"; n 11; "Number of Adverse Events"; 2027-11
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which 10 trials of Brodalumab posted no result?
Posted no result
10 of 10 completed trials
Registrations
NCT01488201, NCT01748539, NCT01782937, NCT01782924, NCT02982005 and NCT02985983, and 4 more
Completion dates
oldest 2012-09; newest 2022-08-05
Show the evidence
Trial
NCT01488201
2012-09
NCT01748539
2013-09
NCT01782937
2014-12
NCT01782924
2015-02
NCT02982005
2018-08-14
NCT02985983
2019-09-23
4 further recorded trials
NCT03960268
2020-06-01
NCT04149587
2022-03-30
NCT04979520
2022-07-25
NCT04061252
2022-08-05
Q9
At the median, Brodalumab's trials enrolled 128 people — anything larger?
Median enrolment
128
Largest enrolment
3500
Registered trials counted
44
Q10
What do 147 spontaneous reports say about Brodalumab — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Brodalumab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 147 reaction mentions were counted: psoriasis 36; arthralgia 33; depression 15; suicidal ideation 13. open-targets-adr · CHEMBL1742996 · 2026-06-24
Show the evidence
psoriasis
36
arthralgia
33
depression
15
suicidal ideation
13
psoriatic arthropathy
12
therapy interrupted
10
4 more recorded rows
oropharyngeal pain
9
arthritis
7
cellulitis
7
cutaneous lymphoma
5
recorded 2026-06-24 · last checked 2026-09-04
Q11
Brodalumab and CYP3A4: shared by which compounds?
CYP3A4 appear in Brodalumab's recorded interaction sentences, 1 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP3A4pharmacokinetics
Drug Interaction Studies In subjects with plaque psoriasis, one week following a single subcutaneous administration of 210 mg brodalumab, the exposure of midazolam (CYP3A4 substrate) was increased by 24% [see Drug Interactions ( 7 )].
recorded 2026-08-30 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 8 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.